P2D, INC

Address

10101 ALLIANCE RD STE 105
CINCINNATI, OH, 45242-4736

http://www.p2dinc.com

Information

DUNS: 182472162
# of Employees: 3

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Activated protein C peptides for radio-mitigation

    Amount: $298,750.00

    ABSTRACT The purpose of the proposed grant application is to further develop a therapeutic regimen focused on radiological nuclear medical countermeasures Very few medical products have been shown to ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. PancreasCHIP- A diagnostic tool for Inheritable Pancreatic Disease

    Amount: $266,046.00

    DESCRIPTION provided by applicant Pancreatitis is a painful condition that may become recurrent or chronic in genetically susceptible individuals Patients with pancreatitis suffer multiple hospita ...

    SBIRPhase I2015Department of Health and Human Services
  3. A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.

    Amount: $1,489,893.00

    DESCRIPTION provided by applicant The goal of this proposal is to develop tumor necrosis factor a TNFa inhibiting compounds as neuroprotectant drugs for treating Alzheimerandapos s disease AD ...

    SBIRPhase II2015Department of Health and Human Services
  4. Novel Alzheimer's Disease Drug Treatment

    Amount: $224,905.00

    DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (A ...

    SBIRPhase I2014Department of Health and Human Services
  5. Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML

    Amount: $224,629.00

    DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the d ...

    SBIRPhase I2014Department of Health and Human Services
  6. A non-myeloablative conditioning regimen for hematopoietic stem cell transplantat

    Amount: $366,718.00

    Abstract Hematopoietic stem cell transplantation (HSCT) has become a standard care for the treatment of many hematologic malignancies and non-malignant diseases such as bone marrow failure and immunod ...

    SBIRPhase I2014Department of Health and Human Services
  7. Rho GTPase inhibitors for refrigerated platelet storage

    Amount: $224,700.00

    ABSTRACT The use of platelet transfusions has increased dramatically since 1980s, but a safe, long-term platelet storage method remains missing. Current practice has platelets stored at 20 to 24 C aft ...

    SBIRPhase I2014Department of Health and Human Services
  8. LIVERCHIP- A diagnostic tool for genetic liver diseases

    Amount: $1,178,516.00

    DESCRIPTION provided by applicant Genetic mutations are known to cause acute and chronic liver diseases and are being increasingly recognized as drivers of phenotype severity As a group these di ...

    SBIRPhase II2014Department of Health and Human Services
  9. Coronary Post-Dilatation Catheter

    Amount: $395,476.00

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Cu ...

    SBIRPhase I2013Department of Health and Human Services
  10. Pharmacological rejuvenation of aged hematopoietic stem cells.

    Amount: $361,403.00

    DESCRIPTION (provided by applicant): The demographic development in most Western countries predicts that age-associated diseases and their prevention will become an important social, economic and med ...

    SBIRPhase I2012Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government